Lawrence S. Zisman

Lawrence S. Zisman

Auto-generated profile, based on publicly available information

Lawrence S. Zisman

Gossamer Bio, Inc., San Diego, CA 92121, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
AGAnna Galkin
Anna Galkin
RSRavikumar Sitapara
Ravikumar Sitapara
BCBryan Clemons
Bryan Clemons
EGEduardo Garcia
Eduardo Garcia
MKMichael Kennedy
Michael Kennedy
LZLawrence S. Zisman
Lawrence S. Zisman
Background Signaling through platelet-derived growth factor receptor (PDGFR), colony stimulating factor 1 receptor (CSF1R), and c-KIT plays a critical role in pulmonary arterial hypertension (PAH). We examined the preclinical efficacy of inhaled seralutinib, a unique small molecule PDGFR/CSF1R/c-KIT kinase inhibitor in clinical development for PAH, in comparison to a proof-of-concept kinase inhibitor, imatinib. Methods Seralutinib and imatinib potency and selectivity were compared. Inhaled seralutinib pharmacokinetics/pharmacodynamics were studied in healthy rats. Efficacy was evaluated in two rat models of PAH: SU5416/Hypoxia (SU5416/H) and monocrotaline pneumonectomy (MCTPN). Effects on inflammatory/cytokine signaling were examined. PDGFR, CSF1R, and c-KIT immunohistochemistry (IHC) in rat and human PAH lung samples and miRNA analysis in the SU5416/H model were performed. Results Seralutinib potently inhibited PDGFRα/β, c-KIT and CSF1R. Inhaled seralutinib demonstrated dose-dependent inhibition of lung PDGFR and c-KIT signaling, and increased bone morphogenetic protein receptor type 2 (BMPR2). Seralutinib improved cardiopulmonary hemodynamics and reduced small pulmonary artery muscularisation and right ventricle hypertrophy in both models. In the SU5416/H model, seralutinib improved cardiopulmonary hemodynamics, restored lung BMPR2 protein levels, and decreased n-terminal prohormone of brain natriuretic peptide (NT-proBNP) more than imatinib. Quantitative IHC in human lung PAH samples demonstrated increased PDGFR, CSF1R, and c-KIT. miRNA analysis revealed candidates that could mediate seralutinib effects on BMPR2. Conclusions Inhaled seralutinib was an effective treatment of severe PAH in two animal models, with improved cardiopulmonary hemodynamics, reduction in NT-proBNP, reverse remodeling of pulmonary vascular pathology, and improvement in inflammatory biomarkers. Seralutinib showed greater efficacy compared to imatinib in a preclinical study.

Verified
Journal Article
Open access
PDF file
SPSoni S. Pullamsetti
Soni S. Pullamsetti
RSRavikumar Sitapara
Ravikumar Sitapara
RORobin Osterhout
Robin Osterhout
AWAstrid Weiss
Astrid Weiss
LCLaura L. Carter
Laura L. Carter
RSRalph Schermuly
Ralph Schermuly
Pulmonary arterial hypertension (PAH) is a complex disorder characterized by vascular remodeling and a consequent increase in pulmonary vascular resistance. The histologic hallmarks of PAH include plexiform and neointimal lesions of the pulmonary arterioles, which are composed of dysregulated, apoptosis-resistant endothelial cells and myofibroblasts. Platelet-derived growth factor receptors (PDGFR) α and β, colony stimulating factor 1 receptor (CSF1R), and mast/stem cell growth factor receptor kit (c-KIT) are closely related kinases that have been implicated in PAH progression. In addition, emerging data indicate significant crosstalk between PDGF signaling and the bone morphogenetic protein receptor type 2 (BMPR2)/transforming growth factor β (TGFβ) receptor axis. This review will discuss the importance of the PDGFR-CSF1R-c-KIT signaling network in PAH pathogenesis, present evidence that the inhibition of all three nodes in this kinase network is a potential therapeutic approach for PAH, and highlight the therapeutic potential of seralutinib, currently in development for PAH, which targets these pathways.

1 September 1998 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
TTTatiana O. Tsvetkova
Tatiana O. Tsvetkova
DFDavid J. Farber
David J. Farber
WAWilliam T. Abraham
William T. Abraham
PKPatty Kelley
Patty Kelley
EEEric Eichhorn
Eric Eichhorn
BLBrian D. Lowes
Brian D. Lowes

1 April 2021 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
MFMariana Faria‐Urbina
Mariana Faria‐Urbina
KUKeith T. Ung
Keith T. Ung
LLLaurie Lawler
Laurie Lawler
LZLawrence S. Zisman
Lawrence S. Zisman
AWAaron B. Waxman
Aaron B. Waxman
Inhalation profiles to support use of dry powder inhalers for drug delivery in patients with pulmonary arterial hypertension have not been reported. We aimed to evaluate the inspiratory flow pattern associated with low and medium flow resistance dry powder inhaler devices (RS01‐L and RS01‐M, respectively) in patients with pulmonary arterial hypertension. This single‐center study enrolled patients with pulmonary arterial hypertension associated with connective tissue disease (n = 10) and idiopathic pulmonary arterial hypertension (n = 10) to measure the following inhalation parameters: inspiratory effort (kPa), peak inspiratory flow rate (L/min), inhaled volume (L), and flow increase rate (L/s2) using the two devices. We identified a trend toward higher mean pulmonary artery pressure in the idiopathic pulmonary arterial hypertension group (50 ± 13 mmHg vs. 40 ± 11 mmHg in pulmonary arterial hypertension associated with connective tissue disease; p = 0.077). On average, peak inspiratory flow rate was higher with RS01‐L vs. RS01‐M (84 ± 19.7 L/min vs. 70.4 ± 13.2 L/min; p = 0.015). In the overall group, no differences between RS01‐L and RS01‐M were observed for inhaled volume, inspiratory effort, or flow increase rate. Inhaled volume with RS01‐L was higher in pulmonary arterial hypertension associated with connective tissue disease vs. idiopathic pulmonary arterial hypertension patients: 1.6 ± 0.4 L vs. 1.3 ± 0.2 L; p = 0.042. For the RS01‐L, inhaled volume correlated with forced expiratory volume in one second (r = 0.460, p = 0.030) and forced vital capacity (r = 0.507, p = 0.015). In patients with pulmonary arterial hypertension associated with connective tissue disease using RS01‐L, both inspiratory effort and flow increase rate were highly correlated with pulmonary vascular compliance (r = 0.903, p = 0.0001 and r = 0.906, p = 0.0001; respectively); while with RS01‐M, inspiratory effort was highly correlated with pulmonary vascular compliance (r = 0.8, p = 0.001). Our data suggest that the use of RS01‐L and RS01‐M dry powder inhaler devices allowed adequate inspiratory flow in pulmonary arterial hypertension patients. The correlation between flow increase rate and pulmonary vascular compliance in pulmonary arterial hypertension associated with connective tissue disease deserves further investigation.

1 June 2021 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
RSRavikumar Sitapara
Ravikumar Sitapara
CSChuluunbaatar Sugarragchaa
Chuluunbaatar Sugarragchaa
LZLawrence S. Zisman
Lawrence S. Zisman
SU5416 plus chronic hypoxia causes pulmonary arterial hypertension in rats and is assumed to occur through VEGFR2 inhibition. Cabozantinib is a far more potent VEGFR2 inhibitor than SU5416. Therefore, we hypothesized that cabozantinib plus hypoxia would induce severe pulmonary arterial hypertension in rats. Cell proliferation and pharmacokinetic studies were performed. Rats were given SU5416 or cabozantinib subcutaneously or via osmotic pump and kept hypoxic for three weeks. Right ventricular systolic pressure and hypertrophy were evaluated at days 14 and 28 following removal from hypoxia. Right ventricular fibrosis was evaluated with Picro‐Sirius Red staining. Kinome inhibition profiles of SU5416 and cabozantinib were performed. Inhibitor binding constants of SU5416 and cabozantinib for BMPR2 were determined and Nanostring analyses of lung mRNA were performed. Cabozantinib was a more potent VEGFR inhibitor than SU5416 and had a longer half‐life in rats. Cabozantinib subcutaneous plus hypoxia did not induce severe pulmonary arterial hypertension. Right ventricular systolic pressure at 14 and 28 days post‐hypoxia was 36.8 ± 2.3 mmHg and 36.2 ± 3.4 mmHg, respectively, versus 27.5 ± 1.5 mmHg in normal controls. For cabozantinib given by osmotic pump during hypoxia, right ventricular systolic pressure was 40.0 ± 3.1 mmHg at 14 days and 27.9 ± 1.9 mmHg at 28 days post‐hypoxia. SU5416 plus hypoxia induced severe pulmonary arterial hypertension (right ventricular systolic pressure 61.9 ± 6.1 mmHg and 64.9 ± 8.4 mmHg at 14 and 28 days post‐hypoxia, respectively). Cabozantinib induced less right ventricular hypertrophy (right ventricular free wall weight/(left ventricular free wall weight + interventricular septum weight) at 14 days post‐hypoxia compared to SU5416. Right ventricular fibrosis was more extensive in the SU5416 groups compared to the cabozantinib groups. SU5416 (but not cabozantinib) inhibited BMPR2. Nanostring analyses showed effects on pulmonary gene expression of BMP10 and VEGFR1 in the SU5416 28 days post‐hypoxia group. In conclusion, selective VEGFR2 inhibition using cabozantinib plus hypoxia did not induce severe pulmonary arterial hypertension. Severe pulmonary arterial hypertension due to SU5416 plus hypoxia may be due to combined VEGFR2 and BMPR2 inhibition.

1 July 2021 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
RSRavikumar Sitapara
Ravikumar Sitapara
TLTuKiet T. Lam
TuKiet T. Lam
AGAneta Gandjeva
Aneta Gandjeva
RTRubin M. Tuder
Rubin M. Tuder
LZLawrence S. Zisman
Lawrence S. Zisman
Pulmonary arterial hypertension (PAH) is a rare disorder associated with high morbidity and mortality despite currently available treatments. We compared the phosphoproteome of lung tissue from subjects with idiopathic PAH (iPAH) obtained at the time of lung transplant with control lung tissue. The mass spectrometry‐based analysis found 60,428 phosphopeptide features from which 6622 proteins were identified. Within the subset of identified proteins there were 1234 phosphopeptides with q < 0.05, many of which are involved in immune regulation, angiogenesis, and cell proliferation. Most notably there was a marked relative increase in phosphorylated (S378) IKZF3 (Aiolos), a zinc finger transcription factor that plays a key role in lymphocyte regulation. In vitro phosphorylation assays indicated that GSK3 alpha and/or GSK3 beta could phosphorylate IKZF3 at S378. Western blot analysis demonstrated increased pIKZF3 in iPAH lungs compared to controls. Immunohistochemistry demonstrated phosphorylated IKZF3 in lymphocytes surrounding severely hypertrophied pulmonary arterioles. In situ hybrization showed gene expression in lymphocyte aggregates in PAH samples. A BCL2 reporter assay showed that IKZF3 increased BCL2 promoter activity and demonstrated the potential role of phosphorylation of IKZF3 in the regulation of BCL mediated transcription. Kinase network analysis demonstrated potentially important regulatory roles of casein kinase 2, cyclin‐dependent kinase 1 (CDK1), mitogen‐associated protein kinases (MAPKs), and protein kinases (PRKs) in iPAH. Bioinformatic analysis demonstrated enrichment of RhoGTPase signaling and the potential importance of cGMP‐dependent protein kinase 1 (PRKG). In conclusion, this unbiased phosphoproteomic analysis demonstrated several novel targets regulated by kinase networks in iPAH, and reinforced the potential role of immune regulation in the pathogenesis of iPAH. The identified up‐ and down‐regulated phosphoproteins have potential to serve as biomarkers for PAH and to provide new insights for therapeutic strategies.